A detailed history of Lindenwold Advisors transactions in Abb Vie Inc. stock. As of the latest transaction made, Lindenwold Advisors holds 15,730 shares of ABBV stock, worth $3.16 Million. This represents 1.44% of its overall portfolio holdings.

Number of Shares
15,730
Previous 15,787 0.36%
Holding current value
$3.16 Million
Previous $2.87 Million 6.12%
% of portfolio
1.44%
Previous 1.54%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$154.79 - $180.76 $8,823 - $10,303
-57 Reduced 0.36%
15,730 $2.7 Million
Q1 2024

May 09, 2024

SELL
$159.82 - $182.1 $48,105 - $54,812
-301 Reduced 1.87%
15,787 $2.87 Million
Q4 2023

Feb 08, 2024

SELL
$137.6 - $154.97 $7,155 - $8,058
-52 Reduced 0.32%
16,088 $2.49 Million
Q3 2023

Oct 19, 2023

SELL
$133.59 - $154.65 $24,580 - $28,455
-184 Reduced 1.13%
16,140 $2.41 Million
Q2 2023

Aug 07, 2023

SELL
$132.51 - $164.9 $312,988 - $389,493
-2,362 Reduced 12.64%
16,324 $2.2 Million
Q1 2023

May 05, 2023

BUY
$144.61 - $166.54 $54,228 - $62,452
375 Added 2.05%
18,686 $2.98 Million
Q4 2022

Feb 13, 2023

BUY
$138.31 - $165.87 $31,396 - $37,652
227 Added 1.26%
18,311 $2.96 Million
Q3 2022

Oct 28, 2022

BUY
$134.21 - $153.93 $25,499 - $29,246
190 Added 1.06%
18,084 $2.43 Million
Q2 2022

Aug 05, 2022

BUY
$137.62 - $174.96 $26,560 - $33,767
193 Added 1.09%
17,894 $2.74 Million
Q1 2022

May 09, 2022

BUY
$131.98 - $163.75 $17,949 - $22,270
136 Added 0.77%
17,701 $2.87 Million
Q4 2021

Feb 14, 2022

BUY
$107.43 - $135.93 $1.89 Million - $2.39 Million
17,565 New
17,565 $2.38 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $356B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Lindenwold Advisors Portfolio

Follow Lindenwold Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindenwold Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Lindenwold Advisors with notifications on news.